Search Results
Your search for all items matches 1841 pages
Showing 1 - 50
Joseph A. Sparano, MD, on Multimodal AI Models for Predicting Breast Cancer Recurrence
Joseph A. Sparano, MD, of the Icahn School of Medicine at Mount Sinai, discusses the performance of experimental multimodal artificial intelligence (AI) models integrating clinical, molecular, and histopathologic features to provide prognostic information for early and late recurrence using primary ...
Jame Abraham, MD, FACP, on HER2-Positive Metastatic Breast Cancer: Choosing a Regimen in Clinical Practice
Jame Abraham, MD, FACP, puts findings from several trials in HER2-positive breast cancer into context, including HER2CLIMB, which investigated tucatinib, trastuzumab, and capecitabine in pretreated patients with metastatic disease; DESTINY Breast-09, which evaluated fam-trastuzumab deruxtecan-nki...
Jame Abraham, MD, FACP, on T-DXd in HER2-Positive Early Breast Cancer: Follow-up Data
Jame Abraham, MD, FACP, discusses follow-up data from the DESTINY Breast-05 and DESTINY Breast-11 trials of fam-trastuzumab deruxtecan-nki (T-DXd) for HER2-positive early breast cancer. DESTINY Breast-05 examined the agent given postneoadjuvantly, while DESTINY Breast-11 evaluated the agent in a...
Jame Abraham, MD, FACP, on a Novel Oral SERD for ER-Positive, HER2-Negative Early Breast Cancer
Jame Abraham, MD, FACP, discusses the global, randomized lidERA Breast Cancer trial. Results from lidERA position giredestrant as a potential new standard of care for patients with estrogen receptor (ER)-positive, HER2-negative stage I to III early breast cancer, marking the first phase III trial...
Case 3: Metastatic HR-Positive/HER2-Negative Breast Cancer With PTEN Loss and Emergent ESR1 Mutation
This is Part 3 of Balancing Benefit and Burden: Managing Toxicities in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Neil Iyengar, Sara Tolaney, and William Gradishar...
Case 2: De Novo Metastatic PIK3CA-Altered HR-Positive/HER2-Negative Breast Cancer and Non–Insulin-Dependent Diabetes
This is Part 2 of Balancing Benefit and Burden: Managing Toxicities in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Neil Iyengar, Sara Tolaney, and William Gradishar...
Case 1: PIK3CA-Altered HR-Positive/HER2-Negative Metastatic Breast Cancer
This is Part 1 of Balancing Benefit and Burden: Managing Toxicities in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Neil Iyengar, Sara Tolaney, and William Gradishar...
Case 3: Cardiac Risk Stratification
This is Part 3 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss a challenging...
Case 2: CDK4/6 Inhibitor Choice in Medically Fragile Patients With Heart Failure
This is Part 2 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss managing...
Case 1: Management of Cardiovascular Risk Factors
This is Part 1 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss cardiovascular ...
Erika Hamilton, MD, on Oral SERDs in Breast Cancer: State of the Science
Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, provides a look at “where we stand in 2025” in the field of oral selective estrogen receptor degraders (SERDs) for patients with estrogen receptor–positive, HER2-negative breast cancer. She discusses the first...
Case 1: First-Line Treatment of HR-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Y537S Mutation
This is Part 1 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 61-year-old female patient who...
Case 3: Leptomeningeal Disease in HER2-Positive Breast Cancer
This is Part 3 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a history...
Case 1: Isolated Brain Relapse in HER2-Positive Breast Cancer
This is Part 1 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a cT2N1,...
Erika Hamilton, MD, on ER-Positive HER2-Negative Advanced Breast Cancer: Vepdegestrant vs Fulvestrant
Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, reviews data from the global, randomized, phase III VERITAC-2 study, which compared vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor degrader, to fulvestrant among patients with...
Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy
Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer...
Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs
Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do...
Stephen K.L. Chia, MD, FRCPC, on Advanced HER2-Negative and ER-Positive Breast Cancer: SERD and AKT Inhibitor
Stephen K.L. Chia, MD, FRCPC, of BC Cancer Agency, reviews data from the phase III CCTG/BCT MA.40/FINER trial of fulvestrant and ipatasertib for advanced HER2-negative, ER-positive breast cancer following disease progression on first-line CDK 4/6 and aromatase inhibitors (LBA1005).
Karen Eubanks Jackson on Receiving the 2025 ASCO Patient Advocate Award
Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early...
Sara M. Tolaney, MD, MPH, FASCO, on PD-L1–Positive Advanced TNBC: First-Line Doublet Comparison
Sara M. Tolaney, MD, MPH, FASCO, of Dana-Farber Cancer Institute and Harvard Medical School, discusses findings from the phase III ASCENT-04/KEYNOTE-D19 study, which compared sacituzumab govitecan-hziy plus pembrolizumab vs chemotherapy plus pembrolizumab in previously untreated patients with...
Mafalda Oliveira, MD, PhD, on How Does Hyperglycemia Affect Treatment of Advanced Breast Cancer?
Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, discusses findings on the incidence and management of hyperglycemia in a subset of patients with prediabetes and/or obesity included in the phase I trial of inavolisib alone and in combination...
Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with...
Nicholas C. Turner, MD, PhD, on INAVO120: Final Overall Survival Analysis
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents final overall survival data from the INAVO120 trial of inavolisib/placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer (Abstract 1003).
Giuseppe Curigliano, MD, PhD, on Patient-Reported Outcomes From EMBER-3
Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with imlunestrant, investigator’s choice of standard endocrine therapy, or imlunestrant plus abemaciclib in ...
Case 1: First-Line Therapy in HR-Positive Metastatic Breast Cancer
This is Part 1 of PI3K Inhibition Strategies for HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Adam Brufsky, Heather McArthur, and Seth Wander discuss the first-line...
Case 3: Second-Line Therapy for HR-Positive/HER2-Positive Metastatic Breast Cancer
This is Part 3 of Evolving Paradigms in the Treatment of HR-Positive/HER2-Positive Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Sara Tolaney, Ian Krop, and Mark Pegram discuss second-line therapy...
Case 2: Next Steps After First-Line Induction Therapy for HR-Positive/HER2-Positive Metastatic Breast Cancer
This is Part 2 of Evolving Paradigms in the Treatment of HR-Positive/HER2-Positive Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Sara Tolaney, Ian Krop, and Mark Pegram discuss how to manage a...
Case 1: De Novo Metastatic HR-Positive/HER2-Positive Breast Cancer
This is Part 1 of Evolving Paradigms in the Treatment of HR-Positive/HER2-Positive Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Sara Tolaney, Ian Krop, and Mark Pegram discuss the treatment of de...
Andrew Tutt, MB ChB, PhD, FMedSci, on OlympiA: High-Risk BRCA-Positive Breast Cancer
Andrew Tutt, MB ChB, PhD, FMedSci, Director of The Breast Cancer Now Toby Robins Research Centre and the Institute of Cancer Research (ICR) and Guy’s Hospital King’s College, London, discusses longer-term follow-up of OlympiA, a phase III, multicenter, randomized, placebo-controlled trial of...
Nan Chen, MD, on Impact of Anthracyclines in High Genomic Risk Node-Negative HR-Positive/HER2-Negative Breast Cancer
Nan Chen, MD, of the University of Chicago Medicine, Chicago, discusses the impact of anthracyclines in high genomic risk node-negative HR-positive/HER2-negative breast cancer (Abstract GS3-03).
Kathryn Newlin, RN, MSN, ANP-BC, on Updates in HR-Positive, HER2-Negative Metastatic Breast Cancer
Kathryn Newlin, RN, MSN, ANP-BC, of Washington University in St. Louis, discusses her presentation on HR+ HER2- metastatic breast cancer from the JADPRO Live conference recently held in Grapevine, Texas. Kathryn covers factors involved in treatment selection for this patient population, including...
Adrienne Waks, MD, on MARGOT/TBCRC052: Phase II Trial in HER2-Positive Breast Cancer
Adrienne Waks, MD, of Dana-Farber Cancer Institute, Boston, discusses the randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab vs paclitaxel/trastuzumab/pertuzumab in patients with stage II-III HER2-positive breast cancer. This trial is being done to determine how well ...
Aditya Bardia, MD, on Destiny-Breast06: An Additional Analysis
Aditya Bardia, MD, of UCLA David Geffen School of Medicine, Los Angeles, presents the additional analysis of the efficacy and safety of trastuzumab deruxtecan vs physician’s choice of chemotherapy by pace of disease progression on prior endocrine-based therapy from DESTINY-Breast06 (Abstract...
Mafalda Oliveira, MD, PhD, on Primary Results of SOLTI VALENTINE
Mafalda Oliveira, MD, PhD, of Vall d’Hebron Institute of Oncology, Spain, presented the primary results of SOLTI VALENTINE, a neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor–positive/HER2-negative early breast cancer (Abstract...
Sibylle Loibl, MD, PhD, on Primary Results of the Randomized, Phase III PADMA Study in HER2-Negative/HR-Positive Metastatic Breast Cancer
Sibylle Loibl, MD, PhD, of the German Breast Group, Neu-Isenburg, Germany, presented primary results of the randomized phase III PADMA trial comparing first-line endocrine therapy plus palbociclib vs standard mono-chemotherapy in women with high-risk HER2-negative/HR-positive metastatic breast...
Tiffany Traina, MD, FASCO, on Advances in the Treatment of HR-Positive Breast Cancer
Tiffany Traina, MD, FASCO, is Vice Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center, where she has been a medical oncologist on the Breast Medicine Service since 2006. Dr. Traina is also the Section Head of the Triple Negative Breast Cancer Clinical Research Program. In ...
Komal Jhaveri, MD, FACP, on Antibody-Drug Conjugates in Breast Cancer
Komal Jhaveri, MD, FACP, is an Associate Professor of Clinical Medicine at Weill Cornell Medical College and a Breast Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center in New York. In this video from The ASCO Post Newreels, Dr. Jhaveri shares a...
Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer
Vered Stearns, MD, is the Director for Translational Breast Cancer Research in the Department of Hematology and Medical Oncology at Sandra and Edward Meyer Cancer Center and Weill Cornell Medical School. Dr. Stearns talks about updates in the management of patients with triple-negative breast...
William Gradishar, MD, on Advances in Endocrine Therapeutic Options for Patients With ER-Positive, HER2-Negative Breast Cancer
William Gradishar, MD, discusses advances in endocrine therapeutic options for patients with estrogen receptor–positive, HER2-negative breast cancer, in follow-up to his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Gradishar is the Betsy Bramsen Professor of Breast...
Sunil S. Badve, MD, FRCPath, on Tumor-Infiltrating Lymphocytes in the Patient With Breast Cancer
Sunil S. Badve, MD, FRCPath, discusses research on tumor-infiltrating lymphocytes in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Badve is Professor, Department of Pathology and Laboratory Medicine, and Vice Chair,...
Charles E. Geyer, Jr, MD, FACP, on Management of the Patient With HER2-Positive Breast Cancer in 2024
Charles E. Geyer, Jr, MD, FACP, discusses the management of patients with HER2-positive breast cancer in 2024, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Geyer is Professor of Medicine and Interim Division Chief of Malignant Hematology and Medical...
Frederick Howard, MD, on the Role of Targeted Therapy and Endocrine Therapy in the Patient With Breast Cancer
Frederick Howard, MD, discusses the role of targeted therapy and endocrine therapy in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Howard is Assistant Professor of Medicine in the section of Hematology/Oncology at the...
Endocrine-Resistant Metastatic Breast Cancer
This is Part 3 of Next-Generation Therapies for Metastatic Hormone Receptor–Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri...
PIK3CA-Mutated Metastatic Breast Cancer
This is Part 2 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri discuss the...
ESR1-Mutated Metastatic Breast Cancer
This is Part 1 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri discuss the...
Sara A. Hurvitz, MD, FACP, on New Therapeutic Strategies for HER2-Positive Metastatic Disease Including Brain Metastases
Sara A. Hurvitz, MD, FACP, of Fred Hutch Cancer Center, discusses her presentation on new therapeutic strategies for HER2-positive metastatic disease including brain metastases. Dr. Hurvitz is Senior Vice President and Director, Clinical Research Division, Fred Hutch Cancer Center, and Professor,...
Kristin Rojas, MD, FACS, on Improving Sexual Health During Breast Cancer Treatment
Kristin Rojas, MD, FACS, of the University of Miami, shares key points from her discussion on improving sexual health during breast cancer treatment. Dr. Rojas is an Associate Professor of Surgery in the DeWitt Daughtry Family Department of Surgery, Division of Surgery, Miller School of Medicine at ...
Joseph A. Sparano, MD, FACP, on Premenopausal HR-positive Early Breast Cancer: What to Do Outside the OFSET Trial?
Joseph A. Sparano, MD, FACP, of Icahn School of Medicine at Mount Sinai, discusses his presentation on premenopausal patients with hormone receptor–positive early breast cancer. Dr. Sparano is the Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics, Chief of the Division of Hematology...
Paolo Tarantino, MD, on the Current and Future Landscape of Antibody-Drug Conjugates
Paolo Tarantino, MD, of Dana-Farber Cancer Institute and Harvard Medical School, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Tarantino is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and...
Aditya Bardia, MD, MPH, FASCO, on Novel Therapies Targeting the Estrogen Receptor
Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on novel therapies targeting the estrogen receptor. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational Research...
